Diamyd Medical receives first regulatory approval to start the Phase III trial DIAGNODE-3 with the diabetes vaccine Diamyd®

Diamyd Medical announces today that The Swedish Medical Products Agency has given approval for the start of DIAGNODE-3, a placebo-controlled precision medicine Phase III trial with the diabetes vaccine Diamyd[®]. The trial is designed to confirm the efficacy and safety of Diamyd[®] in individuals recently diagnosed with type 1 diabetes, who carry the genetically defined haplotype HLA DR3-DQ2.“This is very gratifying and an important milestone for DIAGNODE-3,” says Ulf Hannelius, CEO of Diamyd Medical. ”We continue working at full pace with the applications and approvals in the other